Skip to main content
. 2022 Apr 12;15:3977–3989. doi: 10.2147/IJGM.S352536

Figure 3.

Figure 3

CT scan results of the changes for target lesions in one patient with epithelial ovarian cancer before and after anlotinib combined with PD-1 blockades administration.